Yota Sato

Serum levels of soluble CD163 and CXCL5 may be predictive markers for immune-related adverse events in patients with advanced melanoma treated with nivolumab: a pilot study

Taku Fujimura, Yota Sato, Kayo Tanita et al. · Oncotarget · 2018 · 90 citations · Full text

Medicine, Dermatology, Oncology +17

<scp>HLA</scp>‐<scp>DRB</scp>1*04:05 in two cases of Vogt–Koyanagi–Harada disease‐like uveitis developing from an advanced melanoma patient treated by sequential administration of nivolumab and dabrafenib/trametinib therapy

Taku Fujimura, Yumi Kambayashi, Kayo Tanita et al. · The Journal of Dermatology · 2018 · 80 citations

Medicine, Oncology, Ophthalmology +14

Novel COL4A1 mutation in a fetus with early prenatal onset of schizencephaly

Yota Sato, Jun Shibasaki, Noriko Aida et al. · Human Genome Variation · 2018 · 51 citations · Full text

Medicine, Genetics, Molecular Genetics +17

Bexarotene Reduces Production of CCL22 From Tumor-Associated Macrophages in Cutaneous T-Cell Lymphoma

Kayo Tanita, Taku Fujimura, Yota Sato et al. · Frontiers in Oncology · 2019 · 48 citations · Full text

Medicine, Oncology, Pharmacology +15

Sortilin is required for toxic action of Aβ oligomers (AβOs): Extracellular AβOs trigger apoptosis, and intraneuronal AβOs impair degradation pathways

Ayumi Takamura, Yota Sato, Daisuke Watabe et al. · Life Sciences · 2012 · 36 citations

Life Sciences, Neurobiology, Neuroscience +17